Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Agios Pharmaceutical (AGIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,853,941
  • Shares Outstanding, K 58,711
  • Annual Sales, $ 94,390 K
  • Annual Income, $ -346,030 K
  • 60-Month Beta 2.25
  • Price/Sales 31.16
  • Price/Cash Flow N/A
  • Price/Book 4.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.73
  • Number of Estimates 6
  • High Estimate -1.59
  • Low Estimate -1.91
  • Prior Year -1.19
  • Growth Rate Est. (year over year) -45.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.31 +10.90%
on 05/14/19
59.53 -13.72%
on 04/23/19
-4.61 (-8.24%)
since 04/18/19
3-Month
46.31 +10.90%
on 05/14/19
68.94 -25.50%
on 03/04/19
-4.77 (-8.50%)
since 02/21/19
52-Week
41.63 +23.37%
on 12/24/18
99.82 -48.55%
on 06/20/18
-33.93 (-39.78%)
since 05/21/18

Most Recent Stories

More News
Interesting AGIO Put And Call Options For July 19th

Investors in Agios Pharmaceuticals Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGIO options...

AGIO : 51.36 (+5.66%)
Walmart and Cisco rise while Virtusa and Farfetch stumble

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:

FTCH : 22.01 (+3.87%)
KEM : 17.41 (-0.11%)
AGIO : 51.36 (+5.66%)
VRTU : 43.57 (+0.37%)
FLO : 22.77 (-0.18%)
Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

AGIO : 51.36 (+5.66%)
CELG : 96.25 (+1.50%)
MRUS : 13.66 (+0.74%)
GILD : 66.52 (+1.00%)
Agios to Present Clinical Data from its IDH Program at ASCO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that data from its isocitrate dehydrogenase (IDH) programs...

AGIO : 51.36 (+5.66%)
Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO(R) (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

- TIBSOVO Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo -

AGIO : 51.36 (+5.66%)
Downtrend Call Working As Agios Pharmaceut Stock Falls 16.7% (AGIO)

SmarTrend identified a Downtrend for Agios Pharmaceut (NASDAQ:AGIO) on March 25th, 2019 at $61.98. In approximately 1 month, Agios Pharmaceut has returned 16.66% as of today's recent price of $51.65.

AGIO : 51.36 (+5.66%)
Relatively Good Performance Detected in Shares of Acorda Therapeut in the Biotechnology Industry (ACOR , LXRX , AGIO , INSM , SPPI )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

LXRX : 6.07 (+4.30%)
AGIO : 51.36 (+5.66%)
ACOR : 10.93 (+1.58%)
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

AGIO : 51.36 (+5.66%)
CELG : 96.25 (+1.50%)
PDLI : 3.04 (+2.01%)
MRUS : 13.66 (+0.74%)
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO(R) as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

- TIBSOVO is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy -

AGIO : 51.36 (+5.66%)
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.62% and 38.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AGIO : 51.36 (+5.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade AGIO with:

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company's products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 53.74
1st Resistance Point 52.55
Last Price 51.36
1st Support Level 49.09
2nd Support Level 46.82

See More

52-Week High 99.82
Fibonacci 61.8% 77.59
Fibonacci 50% 70.72
Fibonacci 38.2% 63.86
Last Price 51.36
52-Week Low 41.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar